Researchers develop gene therapies for a variety of diseases by targeting the human liver and delivering therapeutics with the use of adeno-associated virus (AAV) vector delivery systems. While this treatment area is exploding in popularity, scientists face challenges when transitioning from animal models to human clinical trials, such as discrepancies in AAV delivery, efficacy, and toxicity. Humanized liver chimeric mouse models offer a promising alternative to traditional models because they better predict AAV gene therapy success in patients.
Download this case study from PhoenixBio to learn how to select more effective AAV vectors using humanized liver chimeric mouse models.
The Scientist c/o LabX Media Group
1000 N West Street, Suite 1200, Wilmington, Delaware, United States, 19801
Toll Free: 888.788.0328 | Phone: 705.528.6888
Email: privacy@the-scientist.com
© 1986-2022 The Scientist
The Scientist needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.